Academic Journal

Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial
المساهمون: Eugene Han, Ji Hye Huh, Eun Y Lee, Ji C Bae, Sung W Chun, Sung H Yu, Soo H Kwak, Kyong S Park, Byung-Wan Lee, Lee, Byung Wan
بيانات النشر: Wiley-Blackwell
سنة النشر: 2022
مصطلحات موضوعية: Diabetes Mellitus, Type 2* / complications, Type 2* / drug therapy, Dipeptidyl-Peptidase IV Inhibitors* / adverse effects, Double-Blind Method, Humans, Liver, Non-alcoholic Fatty Liver Disease* / complications, Non-alcoholic Fatty Liver Disease* / drug therapy, Piperazines, dipeptidyl peptidase-4 inhibitor, evogliptin, magnetic resonance imaging-derived proton density fat fraction, non-alcoholic fatty liver disease, pioglitazone, type 2 diabetes
الوصف: restriction
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 1462-8902
1463-1326
Relation: DIABETES OBESITY & METABOLISM; J00722; OAK-2022-01593; https://ir.ymlib.yonsei.ac.kr/handle/22282913/188336; T202200885; DIABETES OBESITY & METABOLISM, Vol.24(4) : 752-756, 2022-04
DOI: 10.1111/dom.14623
الاتاحة: https://ir.ymlib.yonsei.ac.kr/handle/22282913/188336
https://doi.org/10.1111/dom.14623
https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14623
Rights: CC BY-NC-ND 2.0 KR
رقم الانضمام: edsbas.CD5906A9
قاعدة البيانات: BASE
الوصف
تدمد:14628902
14631326
DOI:10.1111/dom.14623